Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration

Ahmed Mudawi Musa; Sassan Noazin; E. A.G. Khalil; Farrokh Modabber

doi:10.1016/j.trstmh.2009.07.026

Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration

Ahmed Mudawi Musa, Sassan Noazin, E. A.G. Khalil, Farrokh Modabber

Research output: Contribution to journal › Review article › peer-review

30 Scopus citations

Abstract

Instead of relying on drugs to reduce the parasite burden of leishmaniasis, and waiting for the effector immune response to develop in time to control the parasites, immunotherapy in conjunction with chemotherapy can rapidly induce the effector immune response. With a safe and potent drug plus an affordable therapeutic vaccine (immunostimulant), which remains to be developed, a single visit by patients with visceral or cutaneous leishmaniasis might be sufficient to induce a quick and lasting recovery. Drug toxicity and the emergence of resistance could also be dramatically reduced compared with present long-term monotherapy. Immunotherapy could be an effective addition to chemotherapy for leishmaniasis.

Original language	English (US)
Pages (from-to)	1-2
Number of pages	2
Journal	Transactions of the Royal Society of Tropical Medicine and Hygiene
Volume	104
Issue number	1
DOIs	https://doi.org/10.1016/j.trstmh.2009.07.026
State	Published - Jan 2010
Externally published	Yes

Keywords

Immunochemotherapy
Immunocompromised
Immunostimulation
Immunotherapy
Leishmaniasis
Therapy

ASJC Scopus subject areas

Parasitology
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.trstmh.2009.07.026

Cite this

@article{a24e799712f646bca70fd8428aeb87aa,

title = "Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration",

abstract = "Instead of relying on drugs to reduce the parasite burden of leishmaniasis, and waiting for the effector immune response to develop in time to control the parasites, immunotherapy in conjunction with chemotherapy can rapidly induce the effector immune response. With a safe and potent drug plus an affordable therapeutic vaccine (immunostimulant), which remains to be developed, a single visit by patients with visceral or cutaneous leishmaniasis might be sufficient to induce a quick and lasting recovery. Drug toxicity and the emergence of resistance could also be dramatically reduced compared with present long-term monotherapy. Immunotherapy could be an effective addition to chemotherapy for leishmaniasis.",

keywords = "Immunochemotherapy, Immunocompromised, Immunostimulation, Immunotherapy, Leishmaniasis, Therapy",

author = "Musa, {Ahmed Mudawi} and Sassan Noazin and Khalil, {E. A.G.} and Farrokh Modabber",

year = "2010",

month = jan,

doi = "10.1016/j.trstmh.2009.07.026",

language = "English (US)",

volume = "104",

pages = "1--2",

journal = "Transactions of the Royal Society of Tropical Medicine and Hygiene",

issn = "0035-9203",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Immunological stimulation for the treatment of leishmaniasis

T2 - a modality worthy of serious consideration

AU - Musa, Ahmed Mudawi

AU - Noazin, Sassan

AU - Khalil, E. A.G.

AU - Modabber, Farrokh

PY - 2010/1

Y1 - 2010/1

N2 - Instead of relying on drugs to reduce the parasite burden of leishmaniasis, and waiting for the effector immune response to develop in time to control the parasites, immunotherapy in conjunction with chemotherapy can rapidly induce the effector immune response. With a safe and potent drug plus an affordable therapeutic vaccine (immunostimulant), which remains to be developed, a single visit by patients with visceral or cutaneous leishmaniasis might be sufficient to induce a quick and lasting recovery. Drug toxicity and the emergence of resistance could also be dramatically reduced compared with present long-term monotherapy. Immunotherapy could be an effective addition to chemotherapy for leishmaniasis.

AB - Instead of relying on drugs to reduce the parasite burden of leishmaniasis, and waiting for the effector immune response to develop in time to control the parasites, immunotherapy in conjunction with chemotherapy can rapidly induce the effector immune response. With a safe and potent drug plus an affordable therapeutic vaccine (immunostimulant), which remains to be developed, a single visit by patients with visceral or cutaneous leishmaniasis might be sufficient to induce a quick and lasting recovery. Drug toxicity and the emergence of resistance could also be dramatically reduced compared with present long-term monotherapy. Immunotherapy could be an effective addition to chemotherapy for leishmaniasis.

KW - Immunochemotherapy

KW - Immunocompromised

KW - Immunostimulation

KW - Immunotherapy

KW - Leishmaniasis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=70649087040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70649087040&partnerID=8YFLogxK

U2 - 10.1016/j.trstmh.2009.07.026

DO - 10.1016/j.trstmh.2009.07.026

M3 - Review article

C2 - 19712953

AN - SCOPUS:70649087040

SN - 0035-9203

VL - 104

SP - 1

EP - 2

JO - Transactions of the Royal Society of Tropical Medicine and Hygiene

JF - Transactions of the Royal Society of Tropical Medicine and Hygiene

IS - 1

ER -

Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this